// App-Quantinova.ai

: Dupilumab Significantly Reduces Itch and Hives in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Use of Standard-of-care Antihistamines: Results From a Phase 3 Trial (LIBERTY-CSU CUPID Study A)

Researchers

Presenter

  • Marcus Maurer

Principal Investigators

  • Thomas B. Casale

  • Sarbjit S. Saini

  • Nikhil Amin

  • Allen Radin

  • Bola Akinlade

  • Deborah Bauer

  • Elizabeth Laws

  • Leda P. Mannent

  • Aleksra Stjepanovic

Medical Centers

  • Institute of Biochemistry, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

  • Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany

  • University of South Florida, Tampa, FL

  • Johns Hopkins Bayview Medical Center, MD, USA

  • Regeneron Pharmaceuticals, Inc., Tarrytown, NY

  • Sanofi, Bridgewater, NJ

  • Sanofi, Chilly-Mazarin, France

Locations

  • Germany

  • United States

  • France

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Dupilumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • III

Study Id's

  • NCT04180488

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved